Drug intelligence / Profile preview

COPP-ABV

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

COPP-ABV is a combination chemotherapy regimen containing cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone, doxorubicin (Adriamycin), bleomycin, and vinblastine. This combination works by using different drugs that kill cancer cells through various mechanisms. The regimen is primarily used to treat Hodgkin lymphoma, particularly in advanced stages, and may also be effective for non-Hodgkin lymphoma. Clinical studies have shown high complete response rates, with one study reporting 83.6% complete response rate in previously untreated patients with Hodgkin's disease[2].

Other names: C-MOPP/ABVdCOPP-ABV

Targets

TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNAMicrotubuleMAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on COPP-ABV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COPP-ABV.

Explore the full profile